Open access · CC-BY
via OpenAlex
NMN protects cisplatin-associated AKI via NAD+/SIRT1 pathway
Zhaozhi Wen, Jiazeng Wang, Yihang Yang, Longlong Chen, Xiangge Ji, Dong Liu, Chongxu Shi
Frontiers in Immunology · 2026 · ▲ 1 citations
Abstract
Acute kidney injury (AKI) is a critical public health concern with high morbidity and mortality. The chemotherapy agent cisplatin is widely used for various solid tumors; however, cisplatin-associated AKI (CIS-AKI) is a frequent complication in the clinic. Nicotinamide adenine dinucleotide (NAD + ) is a coenzyme central to metabolism and redox reactions. β-Nicotinamide mononucleotide (NMN), a key precursor of NAD + , has shown protective effects in various disease models, but its role in CIS-AKI remains unclear. In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN. Bulk RNA sequencing revealed marked inflammatory activation and disruption of NAD + metabolism in cisplatin-treated mouse kidneys. NMN administration significantly ameliorated kidney dysfunction, as indicated by reduced plasma creatinine and blood urea nitrogen (BUN) levels, attenuated tubular injury, and decreased expression of kidney injury markers NGAL and KIM-1. It also markedly suppressed kidney inflammation, characterized by reduced IL-6 and IL-18 levels, diminished neutrophil infiltration and macrophage accumulation. Consistently, in vitro , NMN attenuated cisplatin-induced reactive oxygen species (ROS) generation and lactate dehydrogenase (LDH) release in HK-2 cells. Mechanistically, NMN elevated kidney NAD + levels and enhanced SIRT1 expression. These findings demonstrate that NMN protects against CIS-AKI by activating the NAD + –SIRT1 pathway, thereby reducing oxidative stress and inflammation, and suggest its potential as a therapeutic strategy for CIS-AKI.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fimmu.2026.1721884
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Wen, Z., Wang, J., Yang, Y., Chen, L., Ji, X., Liu, D., & Shi, C. (2026). NMN protects cisplatin-associated AKI via NAD+/SIRT1 pathway. <em>Frontiers in Immunology</em>. https://doi.org/10.3389/fimmu.2026.1721884
Vancouver
Wen Z, Wang J, Yang Y, Chen L, Ji X, Liu D, et al. NMN protects cisplatin-associated AKI via NAD+/SIRT1 pathway. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1721884.
BibTeX
@article{zhaozhi2026NMNpro,
title = {NMN protects cisplatin-associated AKI via NAD+/SIRT1 pathway},
author = {Zhaozhi Wen and Jiazeng Wang and Yihang Yang and Longlong Chen and Xiangge Ji and Dong Liu and Chongxu Shi},
journal = {Frontiers in Immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1721884},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Antioxidants 2024
Open access · CC-BY
The Role of Nicotinamide Mononucleotide Supplementation in Psoriasis Treatment
Journal of Clinical Investigation 2020
Open access · OA
Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure
Communications Biology 2026
Open access · CC-BY
Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice
Frontiers in Medicine 2021
Open access · CC-BY
NAD+ Homeostasis in Diabetic Kidney Disease
Kidney international reports 2026
Open access · OA
Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.
Redox Biology 2018
Open access · CC-BY